Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: "As a CRDMO, our impact spans the entire pharmaceutical value chain—from early research to commercial manufacturing—which gives us both the responsibility and the opportunity to lead on sustainability. Achieving SBTi validation for our near-term science-based targets affirms that our climate commitments are grounded in science and aligned with global goals. By embedding low-carbon innovation into every stage of our work, we are demonstrating that sustainable practices can accelerate, not hinder, the delivery of life-changing medicines."

In June 2023, the company joined SBTi and committed to setting company-wide near-term GHG reduction targets. Sai Life Sciences Limited has committed to reduce absolute scope 1 and 2 GHG emissions 58.8% by FY2035 from a FY2024 base year.* Sai Life Sciences Limited also has committed to reduce scope 3 GHG emissions from purchased goods and services, capital goods, fuel- and energy-related activities, upstream transportation and distribution, business travel, and employee commuting 63.8% per INR value added within the same timeframe.* *The target boundary includes land-related emissions and removals from bioenergy feedstocks.

In recent years, Sai Life Sciences has made significant investments and progress in advancing its Sustainability agenda. Some of the notable highlights:

  • In 2023, Sai Life Sciences announced its renewed Sustainable Development Goals (SDG) that charted out its roadmap to achieve specific environmental, social, and governance (ESG) targets by the year ending March 31, 2027. As part of the SDGs, the company has committed to reduce specific greenhouse gas emissions by 30% and replace 70% of its energy requirement with renewable sources.
  • Achieved 96% reliance on renewable energy in FY25 in Bider, reducing 16,038 MT of CO₂ emissions. Today, 54% of our total energy comes from renewable sources. We are on track to achieve 70% by FY27 and 80% by 2030.
  • Through our partnership with DHL GoGreen, we are working to reduce logistics-related emissions by 90%
  • Became the first India-headquartered company to join the PSCI membership.

With SBTi validation, well-defined SDG targets and continued efforts, Sai Life Sciences is positioned to advance its sustainability agenda with accountability, rigor, and long-term impact.

Share article

More News

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more

2025.08.13

Peptide Science & Beyond: Masterclass & Fireside Chat with IISc Professor, Dr. Jayanta Chatterjee

Sai Life Sciences recently hosted Dr. Jayanta Chatterjee, Associate Professor at the Indian Institute of Science (IISc), Bangalore, for two enriching sessions at its campus. The first was the Masterclass Lecture Series, where Dr. Chatterjee addressed a group of scientists at Sai Life Sciences on “Our Adventures in the de novo Design of Helical Macrocyclic […]
Read more